Impact of single versus multiple surgeries in CRSwNP patients undergoing treatment with dupilumab.
Saved in:
| Title: | Impact of single versus multiple surgeries in CRSwNP patients undergoing treatment with dupilumab. |
|---|---|
| Authors: | Alicandri-Ciufelli, Matteo (AUTHOR), Cantaffa, Carla (AUTHOR), Galloni, Costanza (AUTHOR), Fernandez, Ignazio Javier (AUTHOR), Marchioni, Daniele (AUTHOR), Pipolo, Carlotta (AUTHOR), Garzaro, Massimiliano (AUTHOR), Nitro, Letizia (AUTHOR), Dell'Era, Valeria (AUTHOR), Ferella, Francesco (AUTHOR), Campagnoli, Massimo (AUTHOR), Russo, Paolo (AUTHOR), Ghidini, Angelo (AUTHOR), De Corso, Eugenio (AUTHOR), Lucidi, Daniela (AUTHOR) |
| Source: | Acta Oto-Laryngologica. May2025, Vol. 145 Issue 5, p450-456. 7p. |
| Subjects: | Therapeutic use of monoclonal antibodies, Visual analog scale, Sinusitis, Retrospective studies, Descriptive statistics, Respiratory obstructions, Endoscopic surgery, Nasal polyps, Nose, Rhinorrhea, Drug efficacy, Research, Disease relapse, Smell disorders, Endoscopy, Evaluation |
| Abstract (English): | Background: Prior to the introduction of biologic drugs, the natural history of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) was characterized by multiple recurrences, thus necessitating multiple surgical interventions. Aims/Objectives: To understand whether Dupilumab efficacy in recurrent CRSwNP varies based on number of previous surgeries. Materials and Methods: This is a multicentric retrospective study on patients with CRSwNP under Dupilumab, who underwent at least one previous surgery. Correlations between number of previous surgeries and clinical outcomes at baseline and during treatment were investigated. Results: 141 patients were included. Mean number of prior surgeries was 2.19 (median 2; range 1-13). For all patients, significant improvements were observed across all time points. Poorer results were observed in patients subjected to more than one prior surgery in terms of NPS at T2 (p.04), SNOT-22 at T4 (p.03), VAS for olfactory dysfunction at T3 (p.01) and T5 (p.009), VAS for nasal obstruction at T4 (p.047), VAS for rhinorrhea at T4 (p.02), VAS for craniofacial pain at T1 (p.02) and T2 (p.04) and of VAS for sleep disturbances at T1 (p.04). Conclusions and significance: Patients subjected to multiple surgeries have worse outcomes during treatment with Dupilumab, particularly for what concerns craniofacial pain and olfactory dysfunction. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): | 背景：在引入生物药物之前, 慢性鼻窦炎伴鼻息肉 (CRSwNP) 的自然病史以多次复发为特征, 因此需要多次手术干预。 目的：了解 Dupilumab 对复发性 CRSwNP 的疗效是否因既往手术次数而异。 材料和方法：这是一项多中心回顾性研究, 研究对象为接受 Dupilumab 治疗的 CRSwNP 患者。这些患者至少接受过一次手术。探讨了基线和治疗期间既往手术次数与临床结果之间的相关性。 结果：纳入 141 名患者。既往手术平均次数为 2.19（中位数为 2；范围为 1-13）。 对于所有患者, 在所有时间点均观察到显著改善。在接受过一次以上手术的患者中, T2 时的 NPS（p.04）、T4 时的 SNOT-22（p.03）、T3 时的嗅觉功能障碍 VAS（p.01）和 T5 时的嗅觉功能障碍 VAS（p.009）、T4 时的鼻塞 VAS（p.047）、T4 时的流鼻涕 VAS（p.02）、T1 时的颅面疼痛 VAS（p.02）和 T2 时的颅面疼痛 VAS（p.04）以及 T1 时的睡眠障碍 VAS（p.04）的结果较差。 结论和意义：接受过多次手术的患者在使用 Dupilumab 治疗期间的结果较差, 尤其在颅面疼痛和嗅觉功能障碍方面。 [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Oto-Laryngologica is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
